We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Whole Blood Controls Monitor Immunosuppressant Drug Test Precision

By LabMedica International staff writers
Posted on 29 Oct 2012
Print article
Image: Five levels of Lyphocheck Whole Blood Immunosuppressant Control (Photo courtesy of Bio-Rad).
Image: Five levels of Lyphocheck Whole Blood Immunosuppressant Control (Photo courtesy of Bio-Rad).
A lyophilized, third party, human whole blood based control offers five individual levels and includes Cyclosporine, Tacrolimus, and Sirolimus.

The control can be used with immunoassay or chromatographic techniques. Called the Lyphochek Whole Blood Immunosuppressant Control, it was designed for use as an assayed quality control material to monitor the precision of immunosuppressant drug test procedures in the clinical laboratory from low to very high concentrations. Immunosuppressant drugs are typically used in transplant therapy to help minimize organ rejection. Lyphochek Control is supplied as a whole blood based material that can be processed in the same manner as patient samples.

Bio-Rad Laboratories, Inc. (Hercules, CA, USA), a manufacturer and distributor of life science clinical diagnostics and research products, released the Lyphochek Whole Blood Immunosuppressant Control.

The company offers technical support and troubleshooting assistance for the control. The Unity Interlaboratory Program and the Unity Real Time, a data management-software solution designed to improve the effectiveness of quality control processes, are available for use with the Lyphochek Control.

Related Links:

Bio-Rad Laboratories - TDM controls
Bio-Rad Laboratories, Inc.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.